Naomi J. Patel

B‐Cell Depletion Relative to Tumor Necrosis Factor Inhibition Extends the Duration of Viral Shedding in COVID‐19 Among Autoimmune Disease Patients: A Matched Prospective Cohort Study

Liya S. Getachew, Xiaosong Wang, Naomi J. Patel, Zachary S. Wallace et autres

OBJECTIVE: To investigate SARS-CoV-2 viral shedding duration in autoimmune patients using B cell depleting (BCD) therapy or tumor necrosis factor inhibitors (TNFi) and immunocompetent comparators. METHODS: We conducted a matched cohort analysis among participants in POSITIVES, a prospective study enrolling outpatients with …

us (code pays fourni par la source)

Association of oral outpatient antiviral medications for COVID-19 with the risk of post-acute sequelae of COVID-19 at 28 and 90 days in a cohort of individuals with systemic autoimmune rheumatic diseases

Madison Negron, Yi-Xiang Wang, X C Wang, Lauren A. O’Keeffe et autres

us (code pays fourni par la source)

Autoantibodies and Risk for Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease With Comparisons to Idiopathic Pulmonary Fibrosis and Healthy Controls

Rathnam Venkat, Xiaosong Wang, Misti L. Paudel, Suchita P. Nety et autres

A novel cohort to assess longitudinal glucocorticoid toxicity in individuals with rheumatic diseases: objectives, design, and initial baseline characteristics of the LONG-TOX cohort

Naomi J. Patel, Jiaqi Wang, Bohang Jiang, Isha Jha et autres

us, ca (code pays fourni par la source)

Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases

Natalie A. Davis, Jiaqi Wang, Xiaosong Wang, Liya S. Getachew et autres

OBJECTIVE: To investigate respiratory syncytial virus (RSV) vaccine uptake, associations, and breakthrough infection among patients with systemic autoimmune rheumatic diseases (SARDs). METHODS: We performed a retrospective cohort study investigating RSV vaccination among patients with SARDs at Mass General Brigham (Boston, Massachusetts, USA). …

us (code pays fourni par la source)

Ongoing Benefits of SARS-CoV-2 Vaccination and Booster Vaccination 5 Years Following the Start of the COVID-19 Pandemic

Avik Som, Naomi J. Patel

Individuals with systemic autoimmune rheumatic diseases (SARDs) are at increased risk of severe complications of coronavirus disease 2019 (COVID-19) infection, in part due to the use of immunosuppressive medications as well as potential dysregulated immunity.1-4 Vaccine recommendations (eg, pneumococcal, influenza, shingles, SARS-CoV-2) …

us (code pays fourni par la source)

Outcomes of respiratory syncytial virus infection in patients with systemic autoimmune rheumatic disease

J. Enns, Jiaqi Wang, Bohang Jiang, Shruthi Srivatsan et autres

BACKGROUND: Respiratory syncytial virus (RSV) is a common respiratory viral illness which can cause severe outcomes in older and immunosuppressed populations. There is little data regarding RSV outcomes among people with systemic autoimmune rheumatic diseases (SARDs). METHODS: This retrospective cohort study examined …

us (code pays fourni par la source)

Real-World Clinical Outcomes in a Large Health Care System After Avacopan Initiation for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) Involving the Kidneys

Naomi J. Patel, Andrew King, Madison Negron, Zachary K Williams et autres

Background: Avacopan is an adjunctive therapy for adults with severe active GPA/MPA. Real-world data on kidney outcomes at 1 year are limited. Methods: In this retrospective cohort study of patients prescribed avacopan for GPA/MPA from 12/1/21-4/1/24 at Mass General Brigham, we report …

us (code pays fourni par la source)

SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry

Monique Gore‐Massy, Ellison Smith, Jūlija Zepa, Zachary S. Wallace et autres

OBJECTIVE: While COVID-19 vaccination prevents severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analysed the clinical characteristics of patients with rheumatic disease who developed breakthrough COVID-19 after vaccination against SARS-CoV-2. METHODS: We included people partially or fully vaccinated against …

us (code pays fourni par la source)

Impact of long COVID on self-reported disease activity, disability, and quality of life in individuals with inflammatory arthritis

Zachary S. Wallace, Shruthi Srivatsan, Andrew P. King, Xiaosong Wang et autres

us (code pays fourni par la source)

Patients with systemic autoimmune rheumatic diseases remain at risk for hospitalisation for COVID-19 infection in the Omicron era (2022–2024): a retrospective cohort study

Naomi J. Patel, Shruthi Srivatsan, Emily Kowalski, Andrew J. King et autres

OBJECTIVE: To investigate the risk factors for severe acute COVID-19 outcomes in the Omicron era among individuals with systemic autoimmune rheumatic diseases (SARDs). METHODS: We identified patients with confirmed SARDs and COVID-19 (positive PCR and/or antigen test) from 1 September 2022 to …

us (code pays fourni par la source)

Outcomes of Respiratory Syncytial Virus (Rsv) Infection in Individuals with Systemic Autoimmune Rheumatic Disease

J. Enns, Jiaqi Wang, Bohang Jiang, Shruthi Srivatsan et autres

us (code pays fourni par la source)